Casdin Partners Master Fund, L.P. bought $5.1M of LAB
director, owner at STANDARD BIOTOOLS INC.. 4,820,959 shares at an average of $1.07, traded Feb 28, 2025, filed Mar 4, 2025.
Score components
- +15RoleDirector
- +25Trade size$5.1M at market
- +3Relative to holdingsHoldings up 9%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000919574-25-001777, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2025 | POpen-market purchase Common Stockindirect: See footnote | +4,820,959 | $1.07 | $5.1M | 58,846,780 | Mar 4, 2025 |
| Feb 28, 2025 | JOther Common Stockindirect: See footnote | +545,000 | $1.07 | $580k | 59,391,780 | Mar 4, 2025 |
| Feb 28, 2025 | JOther Common Stockindirect: See footnote | -545,000 | $1.07 | $580k | 0 | Mar 4, 2025 |
| Feb 28, 2025 | AGrant or award Common Stock | +58,215 | $1.07 | $62k | 2,806,470 | Mar 4, 2025 |
Related signals
Other insiders at STANDARD BIOTOOLS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | LABsell STANDARD BIOTOOLS INC. | Michael Egholm President & CEO | $5,150 5,473 shares | -0% | |
| 25Weak | LABsell STANDARD BIOTOOLS INC. | Michael Egholm President & CEO | $5,126 5,116 shares | -0% | |
| 25Weak | LABsell STANDARD BIOTOOLS INC. | Michael Egholm President & CEO | $4,861 4,719 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.